average weight loss on glp 1 first month TrimRX A healthier you starts with

What Studies Have NOT Demonstrated in Humans Despite community claims, no controlled human trial has demonstrated: A specific body fat percentage reduction attributable to LR3 IGF-1 cycling A specific lean mass gain figure for the standard 10-day-on / 4-week-off pattern Cardiovascular safety endpoints across repeated cycles Long-term cancer-incidence data for cycled LR3 IGF-1 use Epidemiological data on chronically elevated endogenous IGF-1 has raised theoretical cancer concerns (Yoshida & Delafontaine, 2020), and that concern is one reason community protocols favor short, spaced cycles rather than continuous use

B., Malmlf, K., Johansen, P

This cardiovascular outcomes trial demonstrated that semaglutide reduces major adverse cardiovascular events in people with obesity without diabetes

2014;9(11):e111899